Paper9537252
Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines.
Pulaski BA and 1 other. Cancer Res, 1998. Cited by 344 papers, by iCite.
Cite this record
ConductScience Library. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Papers, record 9537252. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9537252
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines.
- PubMed
- Publication types
- Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| B7-1 Antigen | Major topic |
| Cancer Vaccines | Major topic |
| Histocompatibility Antigens Class II | Major topic |
| Immunotherapy, Active | Major topic |
| Mammary Neoplasms, Experimental | Major topic |
| Neoplasm Metastasis | Major topic |
| Animals | |
| Antimetabolites, Antineoplastic | |
| Cell Division | |
| Disease Models, Animal | |
| Drug Resistance, Neoplasm | |
| Female | |
| Mice | |
| Mice, Inbred BALB C | |
| T-Lymphocytes | |
| Thioguanine | |
| Transfection |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R01 CA52527 | NCI NIH HHS | United States | R01CA052527 | PubMed and NIH |
Source NIH RePORTER
Cited by211
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 344 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42595355 | Turning off methylglyoxal stress: an alternative approach to inhibit MDSC expansion and metastasis in triple-negative breast cancer. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/42595355 | PubMed |
| 42428078 | The MHCII Immune Activation Score predicts risk of recurrence and benefit of taxanes in Basallike and HER2-enriched breast cancer. | medRxiv | 2026 | https://conductscience.org/library/papers/42428078 | PubMed |
| 41639695 | ISG15-driven immune modulation and tumor progression in breast cancer metastasis: insights from single-cell and spatial transcriptomics. | BMC Med | 2026 | https://conductscience.org/library/papers/41639695 | PubMed |
| 41480638 | IGF1R-targeted delivery of a bridged nucleic acid oligonucleotide-peptide conjugate for microRNA-21 inhibition in triple-negative breast cancer. | NAR Cancer | 2025 | https://conductscience.org/library/papers/41480638 | PubMed |
| 41458569 | A Cell Membrane-Coated Gold Nanoparticle-Based Drug Delivery System for Enhanced Antitumor Therapy in Breast Cancer. | Int J Nanomedicine | 2025 | https://conductscience.org/library/papers/41458569 | PubMed |
| 41424840 | Nanoparticle retention enables non-invasive detection of metastases by magnetic particle imaging in murine breast cancer models. | Theranostics | 2026 | https://conductscience.org/library/papers/41424840 | PubMed |
| 40927638 | Targeting Tumor-Associated Hypoxia with Bioreductively Activatable Prodrug Conjugates Derived from Dihydronaphthalene, Benzosuberene, and Indole-based Inhibitors of Tubulin Polymerization. | RSC Med Chem | 2025 | https://conductscience.org/library/papers/40927638 | PubMed |
| 40836337 | CDK4/6 inhibitors synergize with radiotherapy to prime the tumor microenvironment and enhance the antitumor effect of anti-PD-L1 immunotherapy in triple-negative breast cancer. | J Biomed Sci | 2025 | https://conductscience.org/library/papers/40836337 | PubMed |
| 40410902 | Characterization of extracellular vesicle-associated DNA and proteins derived from organotropic metastatic breast cancer cells. | J Exp Clin Cancer Res | 2025 | https://conductscience.org/library/papers/40410902 | PubMed |
| 40389728 | Mitigating radioresistance mechanisms by polymer-lipid manganese dioxide nanoparticles enhances immunogenic cell death and antitumor immune response to facilitate abscopal effect in breast tumor models. | Drug Deliv Transl Res | 2026 | https://conductscience.org/library/papers/40389728 | PubMed |
| 40304334 | Comparative Glycoproteomic Analysis of Mouse 4T1 Breast Cancer Model. | Curr Med Chem | 2025 | https://conductscience.org/library/papers/40304334 | PubMed |
| 40103600 | Cancer metastasis to the bone: Mechanisms and animal models (Review). | Oncol Lett | 2025 | https://conductscience.org/library/papers/40103600 | PubMed |
| 40071025 | Breast cancer preclinical models: a vital resource for comprehending disease mechanisms and therapeutic development. | EXCLI J | 2025 | https://conductscience.org/library/papers/40071025 | PubMed |
| 39629131 | Ultrafast power doppler ultrasound enables longitudinal tracking of vascular changes that correlate with immune response after radiotherapy. | Theranostics | 2024 | https://conductscience.org/library/papers/39629131 | PubMed |
| 39488625 | Screening and validating the optimal panel of housekeeping genes for 4T1 breast carcinoma and metastasis studies in mice. | Sci Rep | 2024 | https://conductscience.org/library/papers/39488625 | PubMed |
| 39189475 | mRNA-Lipid Nanoparticle-Mediated Restoration of PTPN14 Exhibits Antitumor Effects by Overcoming Anoikis Resistance in Triple-Negative Breast Cancer. | Adv Sci (Weinh) | 2024 | https://conductscience.org/library/papers/39189475 | PubMed |
| 39164434 | Interleukin 4 and cancer resistance in glioblastoma multiforme. | Neurosurg Rev | 2024 | https://conductscience.org/library/papers/39164434 | PubMed |
| 39012440 | State of the Art Modelling of the Breast Cancer Metastatic Microenvironment: Where Are We? | J Mammary Gland Biol Neoplasia | 2024 | https://conductscience.org/library/papers/39012440 | PubMed |
| 38543072 | Dual Role of Alchemilla vulgaris L. Extract in Breast Cancer Regression: Reestablishment of Effective Immune Response. | Pharmaceuticals (Basel) | 2024 | https://conductscience.org/library/papers/38543072 | PubMed |
| 38380618 | Decreased Lung Metastasis in Triple Negative Breast Cancer Following Locally Delivered Supratherapeutic Paclitaxel-Loaded Polyglycerol Carbonate Nanoparticle Therapy. | Biomacromolecules | 2024 | https://conductscience.org/library/papers/38380618 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/9537252
GET https://conductscience.org/api/papers/v1/9537252/cited_by?page=2